Annette Clancy joins Lysogene’s Board of Directors

Annette Clancy has been appointed Chair of the Board of Directors of Lysogene, a leading clinical-stage company focused on gene therapy to treat Central Nervous System (CNS) disorders. 

Karen Aiach

Karen Aiach

Ms. Karen Aiach, Founder and CEO of Lysogene, who has led Lysogene in translating its rAAVrh10 lead product for Sanfilippo from bench to bedside in an unprecedented fashion, stated: “This is an ideal time to have such a senior and dynamic life sciences executive join Lysogene. Annette is a leader in the field and her proven track-record in both business development and R&D will allow us to further advance and expand our gene therapy programmes, enhance our research in the field and further develop our business model”.

Clancy was previously a non-executive member of Lysogene’s board but she also had prior roles within the healthcare, life sciences and biotechnology sectors span research and development as well as M&A, partnerships and funding. She will now bring her extensive experience in business development, clinical research, and commercialization of innovative drug therapies to Lysogene. She will be based in the U.K.

Ms. Clancy stated “I am delighted to assume the Chair of the Board at Lysogene at this exciting time when we are expanding and growing the Company to maximise value for shareholders and patients”.

In addition to her role as Chair of Lysogene’s Board of Directors, Ms. Clancy will maintain her role as a non-executive board member of other private and public biotechnology companies. She currently chairs the Board at Genable Technologies (Ireland) and ObsEva Ltd (Switzerland), and she is a non-executive Director on the board of SOBI Inc. (Sweden).

ADVERTISEMENT

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.